This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Other upper respiratory disease
  • /
  • Platelet-Activating Factor (PAF) in Allergic Rhini...
Journal

Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications.

Read time: 1 mins
Published:29th Aug 2019
Author: Muñoz-Cano RM, Casas-Saucedo R, Valero Santiago A, Bobolea I, Ribó P, Mullol J.
Availability: Free full text
Ref.:J Clin Med. 2019;8(9). pii: E1338.
DOI:10.3390/jcm8091338
Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications


Platelet-activating factor (PAF) is a lipid mediator involved in several allergic reactions. It is released from multiple cells of the immune system, such as eosinophils, neutrophils, and mast cells, and also exerts its effect on most of them upon specific binding to its receptor, becoming a pleiotropic mediator.

PAF is considered a potential relevant mediator in allergic rhinitis, with a key role in nasal congestion and rhinorrhoea due to its effect on vascular permeability. Interestingly, despite its potential relevance as a therapeutic target, no specific PAF inhibitors have been studied in humans. However, rupatadine, a second-generation antihistamine with dual antihistamine and anti-PAF effects has shown promising results by both blocking nasal symptoms and inhibiting mast cell activation induced by PAF, in comparison to antihistamine receptor drugs. In conclusion, the inhibition of PAF may be an interesting approach in the treatment of allergic rhinitis as part of a global strategy directed at blocking as many relevant inflammatory mediators as possible.

 

Read abstract on library site

Access full article